Your browser doesn't support javascript.
loading
A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.
Kim, Richard D; Sanoff, Hanna K; Poklepovic, Andrew S; Soares, Heloisa; Kim, Jongphil; Lyu, Jing; Liu, Yingmiao; Nixon, Andrew B; Kim, Dae Won.
  • Kim RD; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Sanoff HK; Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA.
  • Poklepovic AS; Department of Medicine, Virginia Commonwealth University Health System, Richmond, Virginia, USA.
  • Soares H; University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, USA.
  • Kim J; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA.
  • Lyu J; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
  • Liu Y; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
  • Nixon AB; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
  • Kim DW; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Cancer ; 126(15): 3464-3470, 2020 08 01.
Article en En | MEDLINE | ID: mdl-32453456

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Piridinas / Neoplasias del Sistema Biliar / Colangiocarcinoma / Factor D de Crecimiento Endotelial Vascular Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Piridinas / Neoplasias del Sistema Biliar / Colangiocarcinoma / Factor D de Crecimiento Endotelial Vascular Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article